Volume 12, Issue 47 (7-2022)
NCMBJ 2022, 12(47): 51-60 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Karimi N, Kheiri H, Zarrinpour V, Forghanifard M. Investigation of biomarker value of SLC1A2 gene in tissue samples of patients with glioblastoma multiforme. NCMBJ 2022; 12 (47) :51-60
URL: http://ncmbjpiau.ir/article-1-1466-en.html
URL: http://ncmbjpiau.ir/article-1-1466-en.html
Department of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran
Abstract: (2281 Views)
Aim and Background: glioblastoma Multiforme (GBM), astrocytoma grade IV which makes up 53% of all gliomas. It is the most common and deadly primary malignant brain tumor in adults. The mortality rate in glioblastoma multiforme is very high. The aim of this study was to determine the expression of SLC1A2 gene in tumor tissues and margins Healthy subjects with glioblastoma multiform were designed and performed.
Materials and Methods: In this study, 50 tissue samples including 25 tissue samples with glioblastoma multiform disease and 25 healthy tissue samples around the GBM tumor before treatment were collected as control samples. RNA extraction and cDNA synthesis were performed in all samples. SLC1A2 gene expression was investigated using Real-time PCR method. ACTB gene was used as internal control. Statistical analysis of data was done using GraphPad Prism version 8 software. Roc curve was used to check the biomarker value of SLC1A2 gene.
Results: Decreased SLC1A2 gene expression was observed in glioblastoma multiforme samples and its expression was compared with the age, gender and tumor size of the patients. The expression of SLC1A2 gene with the age of the patients was statistically investigated and a significant relationship was observed among people over 50 years old and under 50 years old (P-value˂ 0.05), while this significant relationship was not observed in gender and tumor size (P-value>0.05).
Conclusion: The SLC1A2 gene was less expressed in the tumor tissue of patients with glioblastoma multiforme than in the healthy tissue around the tumor. By examining the ROC curve, it is possible that the SLC1A2 gene can be proposed as a biomarker.
Materials and Methods: In this study, 50 tissue samples including 25 tissue samples with glioblastoma multiform disease and 25 healthy tissue samples around the GBM tumor before treatment were collected as control samples. RNA extraction and cDNA synthesis were performed in all samples. SLC1A2 gene expression was investigated using Real-time PCR method. ACTB gene was used as internal control. Statistical analysis of data was done using GraphPad Prism version 8 software. Roc curve was used to check the biomarker value of SLC1A2 gene.
Results: Decreased SLC1A2 gene expression was observed in glioblastoma multiforme samples and its expression was compared with the age, gender and tumor size of the patients. The expression of SLC1A2 gene with the age of the patients was statistically investigated and a significant relationship was observed among people over 50 years old and under 50 years old (P-value˂ 0.05), while this significant relationship was not observed in gender and tumor size (P-value>0.05).
Conclusion: The SLC1A2 gene was less expressed in the tumor tissue of patients with glioblastoma multiforme than in the healthy tissue around the tumor. By examining the ROC curve, it is possible that the SLC1A2 gene can be proposed as a biomarker.
Type of Study: Research Article |
Subject:
Genetics
Received: 2021/11/13 | Accepted: 2022/01/9 | Published: 2022/04/19
Received: 2021/11/13 | Accepted: 2022/01/9 | Published: 2022/04/19
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
